Receive up-to-the-minute news updates on the hottest topics with NewsHub. Install now.

Cadila Healthcare gains nearly 2% on USFDA nod

16 November, 2018 8:01 AM
95 0
Cadila Healthcare gains nearly 2% on USFDA nod

Shares of Cadila Healthcare rose nearly 2 percent intraday Friday on final approval from USFDA.

Zydus Cadila has received the final approval from the USFDA to market Abacavir and Lamivudine tablets USP, 600 mg/300 mg and Fondaparinux Sodium Injection USP, 2.5 mg/0.5 mL, 5 mg/0.4 mL 7.5 mg/0.6 mL and 10 mg/0.8 mL single-dose.

Abacavir and Lamivudine tablets are used with other antiretroviral medicines to treat Human Immunodeficiency Virus-type 1 (HIV-1) infection.

It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

Fondaparinux Injection is used to treat blood clots in deep veins (deep vein thrombosis) and the lungs (pulmonary embolism). It can also be used to prevent blood clots in patients undergoing certain types of surgeries. It will be manufactured at a partner’s manufacturing site.

At 13:20 hrs Cadila Healthcare was quoting at Rs 357.50, down Rs 2.25, or 0.63 percent on the BSE.


Share in social networks:

Comments - 0